214 related articles for article (PubMed ID: 20002779)
1. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
Hansen BR; Haugaard SB; Jensen FK; Jensen JE; Andresen L; Iversen J; Andersen O
HIV Med; 2010 Apr; 11(4):266-75. PubMed ID: 20002779
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
Sivakumar T; Mechanic O; Fehmie DA; Paul B
HIV Med; 2011 Sep; 12(8):453-62. PubMed ID: 21265979
[TBL] [Abstract][Full Text] [Related]
3. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Falutz J; Potvin D; Mamputu JC; Assaad H; Zoltowska M; Michaud SE; Berger D; Somero M; Moyle G; Brown S; Martorell C; Turner R; Grinspoon S
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):311-22. PubMed ID: 20101189
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
Koutkia P; Canavan B; Breu J; Torriani M; Kissko J; Grinspoon S
JAMA; 2004 Jul; 292(2):210-8. PubMed ID: 15249570
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
[TBL] [Abstract][Full Text] [Related]
6. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S
J Clin Endocrinol Metab; 2010 Sep; 95(9):4291-304. PubMed ID: 20554713
[TBL] [Abstract][Full Text] [Related]
7. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.
Lo J; You SM; Canavan B; Liebau J; Beltrani G; Koutkia P; Hemphill L; Lee H; Grinspoon S
JAMA; 2008 Aug; 300(5):509-19. PubMed ID: 18677023
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
Viganò A; Mora S; Manzoni P; Schneider L; Beretta S; Molinaro M; di Natale B; Brambilla P
J Clin Endocrinol Metab; 2005 Jul; 90(7):4075-80. PubMed ID: 15840750
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
Bickel M; Zangos S; Lutz T; Eisen J; Knecht G; Goebel FD; Crespi CM; Jacobi V; Staszewski S; Klauke S
Scand J Infect Dis; 2008; 40(1):36-9. PubMed ID: 17852925
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.
Falutz J; Allas S; Kotler D; Thompson M; Koutkia P; Albu J; Trottier B; Routy JP; Cote P; Abribat T; Grinspoon S
AIDS; 2005 Aug; 19(12):1279-87. PubMed ID: 16052083
[TBL] [Abstract][Full Text] [Related]
11. Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.
Lindboe JB; Langkilde A; Eugen-Olsen J; Hansen BR; Haupt TH; Petersen J; Andersen O
Infect Dis (Lond); 2016; 48(11-12):829-37. PubMed ID: 27417288
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.
Engelson ES; Glesby MJ; Mendez D; Albu JB; Wang J; Heymsfield SB; Kotler DP
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):379-91. PubMed ID: 12138344
[TBL] [Abstract][Full Text] [Related]
13. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
15. The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.
Kotler DP; He Q; Engelson ES; Albu JB; Glesby MJ
Antivir Ther; 2016; 21(2):107-16. PubMed ID: 25536669
[TBL] [Abstract][Full Text] [Related]
16. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
[TBL] [Abstract][Full Text] [Related]
17. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
[TBL] [Abstract][Full Text] [Related]
18. Ultrasonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles.
Guimarães MM; de Oliveira AR; Penido MG; Queiroz LC; Goulart EM; Greco DB; Machado LJ
Ann Nutr Metab; 2007; 51(1):35-41. PubMed ID: 17356264
[TBL] [Abstract][Full Text] [Related]
19. Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Leung V; Chiu YL; Kotler DP; Albu J; Zhu YS; Ham K; Engelson ES; Hammad H; Christos P; Donovan DS; Ginsberg HN; Glesby MJ
HIV Clin Trials; 2016 Mar; 17(2):55-62. PubMed ID: 27077672
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.
Johannsson G; Mårin P; Lönn L; Ottosson M; Stenlöf K; Björntorp P; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1997 Mar; 82(3):727-34. PubMed ID: 9062473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
